GREG Testing, improving, and co-creating Guidance and Tools for Real World Evidence Generation in Europe and use for Decision-Making in Europe: GREG
- Coordinator
- Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
- Runs
- 1 May 2025 to 30 April 2030
- Status
- Running
- EU funding
- €13.3m
- Total cost
- €26.3m
- Partners
- 57 organisations in 17 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101191967
What the project is doing
In the project's own words, from its summary on CORDIS.
Europe generates real world health data (RWD) that has the potential to inform the development and evaluation of medicines and medical devices. However, multiple barriers remain that limit the access, analysis, interpretation, and use of RWD, hampering its use. Additionally, the limited uptake of existing guidelines for the generation and use of real world evidence (RWE) adds complexity in the use of RWD to inform decision making.
The GREG consortium will leverage the learnings of previous and ongoing key RWE initiatives to fill these gaps by generating, pilot-testing, and disseminating evidence-based guidance and tools for the use of RWE to inform the development and evaluation of medicines, medical devices, and combinations. To achieve these goals, we will work with key stakeholders to iteratively test and improve our guidance and tools, backed by case studies from previous successful and unsuccessful examples.
We will engage with the most relevant European RWE initiatives and access the largest network of RWD partners in Europe, namely the European Health Data and Evidence Network (EHDEN) through our partner, the EHDEN Foundation. Additionally, we will provide multi-stakeholder gatherings (including patient and public representatives) to promote the dissemination, adoption, and implementation of RWE for decision-making in Europe.
Our public and private partners will co-create use cases working closely with key regulatory and health technology experts in bespoke fora. These will be used initially to evaluate existing guidelines, and later to pilot-test the GREG guidance and tools. Our outputs will include training for all involved stakeholders on the use of our guidance and tools, and practical templates to facilitate regulatory and health technology/payer submissions.
Together, these will accelerate access to better medicines and medical devices for European citizens.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Coordinator |
| Sanofi-Aventis gulf F.Z.E. | Dubai | AE | Associatedpartner |
| Amgen | Diegem | Belgium | Participant |
| Edwards Lifesciences Belgium BV | Dilbeek | Belgium | Participant |
| Sanofi Pasteur Limited Canada | Toronto | Canada | Associatedpartner |
| Actelion Pharmaceuticals Ltd | Allschwil | Switzerland | Associatedpartner |
| Edwards Lifesciences SARL | Nyon | Switzerland | Associatedpartner |
| Bayer Aktiengesellschaft | Leverkusen | Germany | Participant |
| Boehringer Ingelheim Internationalgmbh | Ingelheim | Germany | Participant |
| Edwards Lifesciences GmbH | Garching B. Munchen | Germany | Associatedpartner |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Pfizer Hellas S.A. | Athens | Greece | Associatedpartner |
| Edwards Lifesciences SL | Valencia | Spain | Associatedpartner |
| Instituto Aragones De Ciencias De La Salud | Zaragoza | Spain | Participant |
| Janssen Cilag SA | Madrid | Spain | Participant |
| Synapse Research Management Partners SL | Madrid | Spain | Participant |
| Edwards Lifesciences SAS | Guyancourt | France | Associatedpartner |
| Institut De Recherches Internationales Servier | Gif-Sur-Yvette | France | Participant |
| Medtronic France | Boulogne | France | Associatedpartner |
| Sanofi R&d Vaccins | Lyon | France | Associatedpartner |
| Sanofi Winthrop Industrie | Gentilly | France | Associatedpartner |
| Sanofi-Aventis Recherche & Developpement | Gentilly | France | Participant |
| Societe Europeenne De Cardiologie | Biot | France | Participant |
| W.L. Gore et Associés S.A.R.L. | Paris | France | Third party |
| University of Galway | Galway | Ireland | Participant |
| Edwards Lifesciences SRL | Milano | Italy | Associatedpartner |
| Medtronic Italia S.p.A. | Milano | Italy | Associatedpartner |
| W.l. Gore & Associati S.r.l. | Verona | Italy | Participant |
| Erasmus Universiteit Rotterdam | Rotterdam | Netherlands | Participant |
| Getreal Institute | Utrecht | Netherlands | Participant |
| Medtronic Bakken Research Center B.v. | Maastricht | Netherlands | Participant |
| Stichting Eupati Foundation | Utrecht | Netherlands | Participant |
| Stichting European Health Data and Evidence Network | Rotterdam | Netherlands | Participant |
| The Hyve BV | Utrecht | Netherlands | Participant |
| W L Gore & Associates BV | Tilburg | Netherlands | Third party |
| Direktoratet for Medisinske Produkter | Oslo | Norway | Participant |
| Universidade De Aveiro | Aveiro | Portugal | Participant |
| Molnlycke Health Care AB | Goteborg | Sweden | Participant |
| Pfizer AB | Sollentuna | Sweden | Associatedpartner |
| Region Uppsala | Uppsala | Sweden | Third party |
| Aventis Pharma Limited UK | Reading | United Kingdom | Associatedpartner |
| Glaxosmithkline Research & Development Limited | London | United Kingdom | Participant |
| Medtronic Ltd | Watford | United Kingdom | Associatedpartner |
| National Institute for Health and Care Excellence | Manchester | United Kingdom | Participant |
| Pfizer Limited | Sandwich | United Kingdom | Associatedpartner |
| Pfizer R&D UK Limited | Sandwich | United Kingdom | Associatedpartner |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Participant |
| The University of Edinburgh | Edinburgh | United Kingdom | Participant |
| University of Dundee | Dundee | United Kingdom | Participant |
| Bristol-Myers Squibb Company Corp | New York | United States | Participant |
| Edwards Lifesciences Llc | Irvine California | United States | Associatedpartner |
| Janssen Research & Development, LLC | Raritan | United States | Associatedpartner |
| Medical Device Business Services Inc | Warsaw | United States | Associatedpartner |
| Medical Devices & Diagnostics Global Services, LLC | Bridgewater | United States | Associatedpartner |
| Medtronic, Inc. | Minneapolis | United States | Associatedpartner |
| Pfizer Inc | New York City | United States | Participant |
| Sanofi US Services Inc. | Cambridge, Massachusetts | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI